ZymoGenetics Begins Clinical Trial For PEG-Interferon Lambda As Potential Treatment For Viral Infection

... ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced that the company has initiated a Phase 1 safety and pharmacokinetic study of PEG-Interferon lambda (IL-29) in healthy volunteers. The Phase 1 study is part of a clinical development program designed to evaluate PEG-Interferon lambda as a potential treatment for patients with hepatitis C and other viral diseases. [click link for full article] ...